CSL Behring
Search results
CSL. Always Evolving for a Better World. CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need.
CSL Limited was incorporated in 1991 and listed on the Australian Securities Exchange (ASX) in 1994. Today, CSL comprises businesses with longstanding, specialized expertise: CSL Behring, a global leader in rare and serious diseases; its subsidiary CSL Plasma, which operates one of the world’s largest plasma collection networks;
CSL's 2024 R&D Investor Briefing. CSL's 2024 R&D Investor Briefing Webcast will be live from 9am on Tuesday, 22 nd October 2024 (AEDT). To pre-register for the webcast, please visit this link. View our2024 Annual report.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.
CSL is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too. Visit CSL
CSL's latest and archived Annual Reports. CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Together they help ensure people everywhere get the treatments they need.
Today, with the combined expertise of CSL Behring (with oversight to CSL Plasma), CSL Seqirus, and CSL Vifor—and our singular commitment to relentlessly innovate—CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they deserve.
New and exciting opportunities allow us to address previously unmet patient needs and these continue to drive us each day. In addition, CSL continues to build on its capabilities across the R&D value chain, from discovery research to pharmacovigilance to its currently marketed therapies.
The 2021 Annual General Meeting (AGM) of CSL Limited (ABN 99 051 588 348) will be held online on Tuesday, 12 October 2021 at 10am (Melbourne time). Contents 1 Chair and CEO message 2 2 2021 Performance 6 Business performance highlights 6 Financial highlights 7 3 Our Company 8 CSL at a glance 8 Our businesses 8 COVID-19: Our efforts 9
